US 10202397
Anti-cancer compounds targeting Ral GTPases and methods of using the same
granted A61KA61K31/4162A61K45/06
Quick answer
US patent 10202397 (Anti-cancer compounds targeting Ral GTPases and methods of using the same) held by The Regents of the University of Colorado, a Body Corporate expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of Colorado, a Body Corporate
- Grant date
- Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/4162, A61K45/06, A61P, A61P35/00